Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sertraline induces DNA damage and cellular toxicity in Drosophila that can be ameliorated by antioxidants


Sertraline hydrochloride is a commonly prescribed antidepressant medication that acts by amplifying serotonin signaling. Numerous studies have suggested that children of women  taking sertraline during pregnancy have an increased risk of developmental defects. Resolving the degree of risk for human fetuses requires comprehensive knowledge of the pathways affected by this drug. We utilized a Drosophila melanogaster model system to assess the effects of sertraline throughout development. Ingestion of sertraline by females did not affect their fecundity or embryogenesis in their progeny. However, larvae that consumed sertraline experienced delayed developmental progression and reduced survival at all stages of development. Genetic experiments showed that these effects were mostly independent of aberrant extracellular serotonin levels. Using an ex vivo imaginal disc culture system, we showed that mitotically active sertraline-treated tissues accumulate DNA double-strand breaks and undergo apoptosis at increased frequencies. Remarkably, the sertraline-induced genotoxicity was partially rescued by co-incubation with ascorbic acid, suggesting that sertraline induces oxidative DNA damage. These findings may have implications for the biomedicine of sertraline-induced birth defects.


Serotonin (5-hydroxytryptamine, or 5-HT) is a neurotransmitter that regulates several behaviors in the metazoan, such as mood, social behavior, sleep, and food intake1. It is also important for embryogenesis, and contributes to oocyte maturation, vascular remodeling, neural crest migration, craniofacial and limb development, left-right asymmetry, cytoskeletal structure, blastomere adhesion, neural patterning, and gastrulation 2,3,4,5,6. Upon release by a presynaptic neuron into the synaptic cleft, serotonin binds 5-HT receptors on the postsynaptic neuron and initiates downstream signaling. Signaling is attenuated via reuptake from the synapse into the presynaptic neuron by the serotonin transporter (SERT) or via degradation by monoamine oxidase. Imbalanced serotonin levels are associated with several mental disorders, such as anxiety, depression, post-traumatic stress disorder, and obsessive-compulsive disorder, and this reuptake mechanism is often targeted to restore serotonin levels in patients with these disorders. Selective Serotonin Reuptake Inhibitors (SSRIs) block SERT, thus leading to higher serotonin concentration and longer duration of action in the synapse. Disorders of serotonergic signaling can also contribute to metastatic cell behavior7,8,9.

Sertraline hydrochloride, henceforth referred to as “sertraline” and marketed under the brand name Zoloft®, is a commonly prescribed SSRI for numerous disorders10. Preclinical trials with sertraline in laboratory animals reported no evidence that sertraline is genotoxic11 and a small study using peripheral lymphocytes from human patients found no significant effects of sertraline on numbers of chromosome aberrations12. Despite the laboratory studies that used sertraline to perturb ion channels and a number of cellular signaling pathways 13,14,15,16,17,18,19,20,21, sertraline currently has Category C designation by the FDA. This has led to its becoming one of the most frequently used SSRIs by pregnant women22. An analysis performed in 2015 failed to find significant evidence for harmful effects associated with sertraline use during pregnancy23. However, other studies have demonstrated that sertraline usage during pregnancy is linked to adverse short- and long-term effects in children24, including atrial septal defects25, craniosynostosis26, increased risk of omphalocele27, developmental delays and increased risk of autism in males28, increased risk of clubfoot29, elevated risk of persistent pulmonary hypertension30, decreased birth weight31, and preterm births32. These structural phenotypes are in addition to a rich literature discussing behavioral outcomes of SSRI exposure during gestation 33,34.

The phenomenon of withdrawal (neonatal abstinence syndrome) reveals the profound effects that exposure to SSRIs has on embryos35. Similar to the developmental defects described above, the observed withdrawal effects present stochastically in the human population, resulting in debate over the relative risks of exposure. Importantly, regulative developmental mechanisms and physiological as well as genetic heterogeneity of both mother and fetus result in a variability of phenotypes across the population, as has been seen in developmental biology studies in animal model systems36. Because different embryos may succumb to or resist perturbation of specific steps in development, it is critical to comprehensively characterize the means by which sertraline (and other SSRIs) could impact embryogenesis. Disruption of the known developmental roles of serotonergic signaling has been suggested to be one of the routes of defects in some individuals37,38,39. However, it is also possible that sertraline results in genetic, epigenetic, or other cellular abnormalities that affect developmental patterning.

Ethical considerations prevent randomized controlled clinical trials in humans to determine sertraline’s embryonic effects and risk profile. To circumvent these challenges, model organisms have been utilized to investigate the effects of sertraline exposure at both cellular and organismal levels. Studies with Xenopus laevis showed that exposure of tadpoles to sertraline (0.1–10 μg/L) resulted in developmental toxicity40. Furthermore, mice exposed to low levels (10 μM) of sertraline develop craniofacial abnormalities, due to interference with serotonin signaling important for normal craniofacial development15.

Drosophila is one of the premiere organisms for studying developmental processes, and is a powerful model for discovery of mechanisms of relevance to human medicine including cancer, neurobiology, and left-right asymmetry41,42,43, all of which are areas where SSRIs have been strongly implicated. The genome of Drosophila melanogaster contains homologs of ~75% of human disease-related genes44. Drosophila utilize serotonin as a neurotransmitter in the nervous system and as a small molecule in early development45,46 and have serotonin receptor homologs. Although no monoamine oxidase has been described in Drosophila, their genome does encode a single serotonin reuptake transporter, named SerT47. Thus, we took advantage of this powerful developmental model to search for novel mechanisms for sertraline action in development, specifically focusing on its ability to disrupt genetic integrity.

Only one study has been published investigating the genotoxicity of sertraline in Drosophila. Using an assay called the somatic mutation and recombination test (SMART), the authors showed that citralopram, another SSRI, caused dose-dependent genotoxicity, but the results with sertraline were inconclusive48.

To further investigate possible genotoxic effects of sertraline in Drosophila and to identify possible causes for the sertraline-related birth defects in humans, we performed a series of experiments at larval and adult stages to determin the impact of sertraline on development and survival. In addition, we incubated larval wing disc tissues with sertraline to investigate changes in cellular markers related to cell death and DNA damage. While exposure of female adult flies to sertraline had no effects on egg laying or hatching, larval exposure led to delays in developmental progression and to impaired viability. Mechanistically, sertraline induced oxidative damage of DNA, which caused cellular apoptosis in tissues necessary for proper development. Strikingly, the cellular damage induced by sertraline could be rescued by antioxidant supplementation. These results establish sertraline as detrimental to fly development, elucidate a new mechanism of its developmental toxicity, and for the first time, provide a potential avenue for mitigation of its adverse effects on embryogenesis that is highly compatible with human patient use.


Sertraline-treated adult females exhibit no difference in fecundity and embryo hatching frequency

We began by investigating the effects of sertraline ingestion on the quantity and quality of eggs laid by adult females. Cohorts of eight females 3–4 days of age were fed using capillary feeders in a modified CAFE apparatus49. Each apparatus had capillaries filled with either a 5% sucrose solution or 5% sucrose with 250 μg/mL of sertraline, a non-toxic concentration for adult Drosophila48. Although the flies consumed less liquid in the apparatus that contained sertraline solution, we were successful in exposing the adult females to the drug via this method (Fig. 1a).

Figure 1

Sertraline consumption does not impact fecundity or egg hatching frequency in Drosophila. (a) Amount of liquid consumed by 8 adult female flies during 8 hours from a single capillary tube in a CAFE apparatus. Each tube contained either 5% sucrose or 250 μg/ml sertraline in 5% sucrose. N = 30, error bars represent SEM. p < 0.0001, unpaired two-tailed t test. (b) Egg laying calculated as the number of eggs laid by one female per hour after treatment with either sucrose or 250 μg/mL sucrose + sertraline solution. N = 7, error bars represent SEM. p = 0.72, unpaired two-tailed t-test. (c) Percentage of eggs hatched one day and two days after egg laying (AEL) by mothers fed either sucrose solution or 250 μg/ml sertraline solution. N = 5–7 replicates for each condition, error bars represent SEM. p = 0.18 after 1 day and p = 0.11 after 2 days, unpaired two-tailed t-test.

Females that were fed only sucrose or sertraline were then placed into a cage with equal numbers of male flies and the number of eggs laid by the females in an 18-hour period was counted. Compared to sucrose, we found no significant difference in fecundity of female flies that drank sertraline-containing solutions (Fig. 1b). On average, female flies fed plain sucrose laid 1 egg every 2.15 hours, while females fed sucrose with sertraline laid 1 egg every 2.34 hours (p = 0.72).

In addition, there was no significant difference in the number of eggs that hatched between the sertraline-fed and control flies (Fig. 1c). One- and two-day hatching frequencies for eggs laid by control females were 84% and 91%, compared to frequencies of 78% and 87% for sertraline-treated females (p = 0.11). To determine if sertraline fed to adult females affected the development of their progeny, we allowed larvae from these eggs to develop into adulthood. Of more than five hundred progeny examined, no obvious morphological or phenotypic differences were noted for progeny from the sertraline-treated females. Thus, while we cannot rule out subtle effects on development, sertraline-fed females do not appear to produce offspring with obvious morphological defects.

Sertraline-treated larvae display delayed development and decreased survival

Unlike human development, which takes place in utero and exposes the fetus to sertraline ingested by its mother, Drosophila embryonic development takes place outside of the mother in an egg that is protected from the environment through an impermeable vitelline membrane and chorion. Larvae which hatch from the egg continue development, paralleling the various stages of organogenesis and remodeling that occur in embryos of all species. After hatching, Drosophila larvae consume food and grow through three instar stages, each lasting approximately 24 hours. At the end of the third instar stage, they cease eating and enter the wandering third instar stage, which lasts for several hours and is followed by a cessation of movement and pupariation. During the pupal stage, which lasts approximately 3–4 days, they undergo metamorphosis and then emerge as adult flies.

We wanted to test whether direct exposure to sertraline might affect Drosophila during its various developmental stages. Repeated attempts to introduce sertraline directly into eggs drastically reduced the viability of the embryos. Therefore, we turned to an established larval feeding protocol, in which larvae consume sertraline-containing food throughout their development48. First instar larvae derived from an Oregon-R stock of flies were placed onto food containing different concentrations of sertraline and their rate of development to various developmental stages was quantified and compared to larvae placed in vehicle-containing food (see Methods).

We chose the transition to the wandering third instar stage as our first developmental time point. We observed a dose-dependent effect for development to wandering third instar larvae, with significant delays observed for the two highest concentrations of sertraline (Fig. 2a). In addition, there was an overall decrease in the survival in larvae treated with sertraline, with only 33% of first instar larvae treated with the highest sertraline concentration surviving to third instar stage, compared to 80% for the controls.

Figure 2

Sertraline delays Drosophila development and reduces survival frequency. (a) Cumulative percentage of wandering third instar larvae following placement of 20–25 Oregon-R first instar larvae into food containing various concentrations of sertraline at day 0. (b) Cumulative percentage of surviving third instar larvae that developed to adulthood following placement of first instar larvae into food containing various concentrations of sertraline at day 0. Each trial lasted for at least 15 days, with no additional changes observed after day 13. N = 4–7 trials for each treatment, error bars represent SEM. *p < 0.05 and ***p < 0.001 (one-way ANOVA with Bonferroni correction).

A similar trend was observed for development from third instar larvae to adulthood (Fig. 2b). For this analysis, we counted the number of adults that eclosed from their pupal cases on successive days and calculated the percentage of adults relative to the number of total third instar larvae that we obtained for each treatment. The developmental delay to the mature adult stage for the highest concentrations of sertraline was similar to the delay seen for the transition from first to third instar larvae, suggesting that the overall delay in development occurred during the larval stages, when the sertraline-containing food was being consumed. However, we also observed a further decrease in survival between the third instar and adult stages for the highest concentrations of sertraline. In the control experiments, over 98% of the wandering third instar larvae survived to adulthood, while only 33% of the third instar larvae raised in the 50 μg/mL sertraline-containing food successfully pupated and eclosed as adults. Therefore, sertraline continues to affect Drosophila viability beyond the larval period when it is being actively ingested.

Sertraline affects Drosophila development independently of serotonin-mediated effects

The developmental delays and decreased survival caused by exposure to sertraline could be caused by changes in serotonin levels due to inhibition of the serotonin reuptake mechanism or by genotoxicity of sertraline itself. To distinguish between these two possibilities, we repeated the larval feeding experiments with flies lacking the sole serotonin reuptake transporter (hereafter referred to as SerT knockout or SerT −/− flies). We chose a sertraline concentration of 10 μg/ml, where we previously observed moderate effects on developmental timing, reasoning that in the SerT knockout flies, any additional developmental delays phenotypes observed in the presence of sertraline treatment could be attributed to genotoxic effects of sertraline itself, rather than its effects on the serotonin transporter. As a control, we measured developmental progression in isogenic flies with an intact SerT gene (see Methods).

As observed with the Oregon-R flies, there was approximately a 1-2 day developmental delay from first-instar to wandering third instar larvae in the presence of 10 μg/mL sertraline, for both the SerT knockout and SerT wild-type stocks (Fig. 3a). Similarly, sertraline-treated flies from both stocks exhibited a delay in development between the wandering third instar and adult stages (Fig. 3b). While the flies lacking SerT did have a slightly delayed transition from first to third instar larvae in the absence of sertraline, this developmental delay was ameliorated by the time the flies reached adulthood. In addition, we observed no increase in sertraline-mediated lethality in the SerT knockout larvae compared to SerT wild-type larvae. From these data, we conclude that while a portion of the larval developmental delays caused by sertraline ingestion may be due to changes in serotonin levels, most of the sertraline-induced delays and lethality is independent of its effects on serotonin signaling. Thus, we next examined its genotoxic potential.

Figure 3

The effects of sertraline on development are mostly independent of its effects on serotonin signaling. (a) Cumulative percentage of wandering third instar larvae following placement of 20–25 first instar larvae into food containing 10 μg/ml sertraline at day 0. (b) Cumulative percentage of surviving third instar larvae that developed to adulthood following placement of first instar larvae into food containing 10 μg/ml sertraline at day 0. Each trial lasted for at least 15 days, with no additional changes observed after day 13. SerT −/− flies lack the SerT serotonin reuptake channel and SerT +/+ flies possess a wild-type copy of the SerT gene in an isogenic background. N = 4 replicates for SerT −/− and 3 replicates for SerT +/+, error bars represent SEM.

Sertraline induces apoptosis and DNA damage in wing imaginal discs

In Drosophila, larval imaginal disc tissues become adult structures, such as eyes, wings, and antennae, following metamorphosis. The induction of DNA damage in imaginal disc tissues results in cell death and developmental delays50,51,52. We hypothesized that sertraline might induce DNA double-strand breaks, the accumulation of which could result in apoptosis in larval imaginal discs, developmental delays, and organismal lethality. To test this hypothesis, we measured levels of DNA damage following sertraline treatment in cultured wing imaginal discs of SerT knockout third instar larvae. We have previously shown that cells in cultured imaginal discs can survive and continue to divide for at least five hours53. In Drosophila, phosphorylation of the histone H2A variant on serine-137 (γ-H2Av) occurs upon double-strand break formation and the number of γ-H2Av foci is roughly proportional to the number of breaks 54,55. Strikingly, a five-hour incubation of wing imaginal discs with 10 μg/mL sertraline resulted in an average three-fold increase in the number of γ-H2Av foci (Fig. 4a,b). Untreated wing discs displayed 10 ± 11 γ-H2Av foci/micron2, while sertraline treated discs had an average of 32 ± 20 foci/micron2 (Fig. 4c), indicating that sertraline treatment induces higher levels of DNA damage in proliferating discs.

Figure 4

Sertraline causes accumulation of DNA double-strand breaks and cell death in wing imaginal discs. (a and b) Wing imaginal discs dissected from SerT −/− wandering third instar larvae were treated for 5 hours with DMSO or 10 μg/ml sertraline and stained with antibodies that recognize phosphorylated γ-H2Av. (c) Quantification of γ-H2Av foci per square micron in control and sertraline treated discs. γ-H2Av foci were counted and normalized to the area of each wing disc, measured from DAPI-stained images. N = 50 discs for control and 47 for sertraline treatment, error bars represent SEM. ***p < 0.001 by unpaired t test with Welch’s correction. (d and e) Wing imaginal discs dissected from SerT −/− wandering third instar larvae, treated with DMSO or 10 μg/ml sertraline, and stained with antibodies against cleaved Dcp-1. (f) Quantification of the number of Dcp-1 foci per square micron in control and sertraline-treated discs. Dcp-1 foci were counted and normalized to the area of each wing disc, measured from DAPI-stained images. N = 22 discs for control and 24 for sertraline treatment, error bars represent SEM. ***p = 0.0005 by unpaired t test with Welch’s correction.

To determine whether the elevated levels of DNA damage also lead to increased cell death, we monitored apoptosis via staining of cleaved death caspase-1 (Dcp-1), which is an effector caspase that promotes degradation of target proteins during apoptosis56,57. Wing discs cultured in the absence of sertraline displayed expected patterns of apoptosis, with Dcp-1 foci clustered mostly towards the top of the discs (Fig. 4d) and little in the middle folded “frown” region58. Although the number of apoptotic cells in sertraline treated discs was more variable, on average the treated discs had three-fold greater numbers of Dcp-1 foci compared to the control discs. Thus, exposure of tissues to sertraline for just a few hours can induce DNA damage in the form of double-strand breaks and lead to excessive cell death that correlates with a delay in organismal development.

Antioxidant supplementation can ameliorate DNA damage induced by sertraline exposure

Beyond its extracellular interactions with the serotonin transporter, sertraline can freely diffuse into cells, and its movement is accelerated by vacuolar proton ATPases59. Although sertraline’s interactions with genetic material have not been investigated in vivo, sertraline does have affinity for the minor groove of DNA60, indicating its potential to interact with an organism’s genetic material once inside the cell. Interestingly, serotonin can act as a pro-oxidant of DNA61 and induce double strand breaks in the presence of copper ions62. Thus, we hypothesized that sertraline, or one of its metabolic breakdown products, might induce oxidative DNA damage that could eventually lead to the formation of double-strand breaks.

To test whether sertraline might increase the amount of reactive oxygen species, we stained sertraline-treated SerT knockout wing imaginal discs with dihydroethidium (DHE). DHE is a compound that can diffuse through cell membranes and produces a red fluorescent ethidium product upon reaction with superoxide radicals63. Interestingly, we observed more overall DHE staining in sertraline-treated discs than in vehicle-treated controls (Fig. 5a,b), although the intensity of staining varied in different regions of each disc. Thus, sertraline may increase the concentration of superoxide radicals in vivo.

Figure 5

Addition of ascorbic acid ameliorates sertraline-induced increases in cell death and DNA damage. (a and b) Wing imaginal discs dissected from SerT −/− wandering third instar larvae were treated for 5 hours with DMSO or 500 μg/ml sertraline + DMSO and stained with dihydroethidium to indicate presence of superoxide ions. (c) Relative number of cleaved Dcp-1 foci per square micron in SerT −/− wing imaginal discs treated with 10 μg/ml sertraline plus increasing concentrations of ascorbic acid. Dcp-1 foci were counted and normalized to the area of each wing disc, measured from DAPI-stained images. For each trial, N ≥ 7 discs for sertraline-only groups and ≥8 discs for each concentration of ascorbic acid, error bars represent SEM. *p < 0.05, **p < 0.01 by ANOVA with Bonferroni correction. (d) Quantification of γ-H2Av foci per square micron for discs treated with 10 μg/ml sertraline or 10 μg/ml sertraline plus 8 mM ascorbic acid. N = 26 discs for sertraline and 31 discs for sertraline + ascorbic acid, error bars represent SEM. **p < 0.01 by unpaired t test with Welch’s correction.

If sertraline’s mechanism of toxicity induction is indeed via oxidative damage, we reasoned that supplementation of an antioxidant might mitigate this toxicity and prevent cell death. To investigate this, we tested the ability of increasing concentrations of ascorbic acid, a known antioxidant, to affect the sertraline-mediated increase in apoptotic cell death observed in SerT knockout wing imaginal discs. Indeed, we observed that increasing concentrations of ascorbic acid resulted in decreases in cell death associated with sertraline treatment (Fig. 5c). Addition of 0.2, 4, 8, and 16 mM concentrations of ascorbic acid led to a 1.7-, 2.3-, 3-, and 10-fold decrease in Dcp-1foci/micron2, respectively, compared to sertraline-treated control discs (Fig. 5c). At a dose of 16 mM, almost no Dcp-1 foci were observed (1.9 foci/micron2, compared to 20.8 foci/micron2 in the sertraline only control).

To determine whether ascorbic acid could also modulate the increase in DNA double-strand breaks observed with sertraline, we employed immunostaining against γ-H2Av using SerT knockout wing imaginal discs treated with 10 μg/mL sertraline and 8 mM ascorbic acid. Strikingly, this concentration of ascorbic acid resulted in a 5.9-fold decrease in γ-H2Av foci (6.3 ± 4.9 foci/micron2 in sertraline-treated discs supplemented with ascorbic acid, compared to 37.5 ± 17.0 foci/micron2 with just sertraline) (Fig. 5d). Thus, antioxidant treatment is capable of ameliorating both the DNA damage and cell death observed with sertraline exposure.

Antioxidant supplementation rescues delayed development and decreased survival of sertraline-treated larvae

Based on the immunostaining results, which show that the addition of ascorbic acid can largely abolish the negative genotoxic effects of sertraline, we performed development tracking assays to determine if the beneficial effects extend to the organismal level. First instar SerT knockout larvae were placed on food containing 50 μg/mL sertraline or 50 μg/mL sertraline + 8 mM ascorbic acid. Remarkably, the sertraline-mediated developmental delays were decreased when ascorbic acid was included in the food. Addition of ascorbic acid increased the rate of development of sertraline-treated larvae from first instar to third instar by 2-3 days (Fig. 6a) and from first instar to adulthood by a similar amount of time (Fig. 6b), although progression to these developmental stages was still slower than that of SerT knockout larvae not exposed to sertraline (compare Fig. 3 to Fig. 6). In addition, ascorbic acid significantly increased the percentage of sertraline-treated larvae that survived to adulthood (Fig. 6c). The effect of ascorbic acid on development was sertraline-specific, as inclusion of 8 mM ascorbic acid in food not containing sertraline did not significantly affect developmental rate from third instar larvae to adulthood (Fig. 6d). Overall, these data suggest that antioxidants can decrease sertraline-induced oxidative DNA damage in Drosophila, promoting regular development and survival.

Figure 6

Addition of ascorbic acid rescues developmental and survival defects caused by larval exposure to sertraline. (a) Cumulative percentage of wandering third instar larvae following treatment of SerT −/− first instar larvae with 50 μg/ml of sertraline or 50 μg/ml sertraline + 8 mM ascorbic acid. N = 4 independent trials, error bars represent SEM. (b) Cumulative percentage of eclosed adults (number of adults/number of third instar larvae) following treatment of SerT −/− first instar larvae with 50 μg/ml sertraline or 50 μg/ml sertraline + 8 mM ascorbic acid. N = 4 independent trials, error bars represent SEM. (c) Total percentage of first instar larvae that survived to adulthood in the presence of 50 μg/ml sertraline or 50 μg/ml sertraline + 8 mM ascorbic acid. N = 4 independent trials, **p = 0.0025 by unpaired T test with Welch’s correction. (d) Cumulative percentage of eclosed adults (number of adults/number of third instar larvae) following treatment of SerT −/− first instar larvae with water or 8 mM ascorbic acid. N = 4 independent trials, error bars represent SEM.


Sertraline induces DNA damage and cell death stochastically, mimicking its pattern of effects on human development

Because sertraline is one of the most commonly prescribed antidepressants22, a better understanding of the mechanistic basis behind the birth defects sporadically observed in children of mothers taking the drug is needed. Here, we utilized a Drosophila model system to determine the effects that sertraline may have on metazoan development. Our initial attempts to test the effects of feeding sertraline to females had no apparent impact, as we failed to see any obvious morphological defects in the embryos, larvae, or adult progeny derived from these females. Because most of the egg development and patterning in these females took place prior to sertraline exposure, this result is perhaps not surprising. Future work using quantitative morphometrics and transcriptional, proteomic, and epigenetic markers will be needed to delineate potential additional phenotypes that may not have been seen in our analysis.

We then turned to a larval feeding protocol, which exposes the developing organism to a physiologically relevant amount of sertraline during a critical stage of development. Although all larval tissues are likely exposed to the drug, we focused on imaginal discs as the target tissue. In Drosophila larvae, these discs contain rapidly dividing diploid cells that are preserved during metamorphosis and eventually form many of the external structures of the adult fly. When cultured ex vivo, cells within the discs continue to rapidly proliferate and maintain DNA damage checkpoints, making them a good model for early cell divisions in human embryos. The concentration of sertraline in the imaginal disc assays was within an order of magnitude of the estimated bioavailability of sertraline in humans64. Discs treated ex vivo with sertraline experienced high levels of oxidative stress, increased DNA damage, and heightened levels of apoptosis. Because these cellular processes are likely to be associated with mutagenesis, we anticipate that our findings may have implications for human developmental processes that occur in the presence of sertraline.

Notably, we observed that these effects are highly variable, paralleling the stochastic nature of sertraline-correlated birth defects in humans. For example, while the overall effect of sertraline ingestion by larvae was a general slowing of development, some sertraline-treated larvae developed at the same rate as untreated larvae. A possible explanation for this variability could be that larvae consumed different amounts of drug-containing food, resulting in variability in drug concentration between individuals. However, the amount of sertraline-induced DNA damage and apoptosis in wing imaginal discs also varied widely, with the distributions for both appearing to be almost bimodal (Fig. 4). The reasons for this are not known, but because the Drosophila in our experiments were genetically homogenous, the variability is likely due to stochastic differences in cellular responses to sertraline and not to genetic differences. This represents an exciting model system for future studies of variability and non-genetic heterogeneity, as physiological variability and stochasticity are now an important aspect of areas of developmental biology65 as well as cancer biology7,66.

Prior research has been mixed with regards to the genotoxic potential of sertraline. Pre-clinical trials did not find evidence for genotoxicity in mice, rats, rabbits, or dogs11 and a single human study that measured chromosome aberrations by cytogenetic staining showed no significant effect of sertraline12. In contrast, other investigations demonstrated that sertraline treatment induces apoptosis in human cancer cell lines67, inhibits cell proliferation, and decreases cellular viability68,69. The only other sertraline study in Drosophila showed mutagenicity at certain concentrations, but a dose-response effect was not observed48. Our study supports a model in which highly proliferative cells may be particularly sensitive to sertraline exposure, possibly including certain cell populations in a developing fetus.

Partial rescue of sertraline-mediated effects by antioxidant supplementation

While a considerable literature on the risks associated with SSRIs exists, the debate has been largely about weighing risks to the mother (by avoiding SSRI use) vs. risks to the fetus (via exposure). Optimal care of both patient populations, as well as insight into molecular mechanisms, thus hinge on the identification of potential treatments that could reverse deleterious effects of SSRI therapies. To our knowledge, no prior studies have addressed the issue of how sertraline-induced damage could be prevented; we thus focused on validating one potential candidate approach to this problem, identified via the mechanistic information obtained in our study.

Based on the increased numbers of DNA double-strand breaks in sertraline-treated imaginal discs, we hypothesized that sertraline might induce oxidative damage, the repair of which could result in DNA single-strand breaks that are converted to double-strand breaks in replicating cells. We observed a decrease in DNA damage and apoptotic cell markers in sertraline-treated wing imaginal discs in the presence of the antioxidant ascorbic acid. In addition, larvae that ate food containing sertraline and ascorbic acid developed faster and had increased survival compared to larvae that ingested only sertraline. Together, these findings support a model that sertraline promotes genotoxicity through the induction of oxidative damage, which may have a greater (but not exclusive) effect on the viability of rapidly dividing cells.

It is important to note that while ascorbic acid decreased the cellular markers of sertraline-induced DNA damage to a level observed in larvae not exposed to sertraline, the developmental progression of larvae consuming sertraline and ascorbic acid was still slower than those of larvae not consuming sertraline. Thus, sertraline may have additional detrimental effects on cells, independent of its ability to induce DNA damage and possibly linked to an increased concentration of extracellular serotonin. Indeed, the observation that larvae lacking the serotonin reuptake channel develop slower and have slightly reduced survival compared to normal larvae (Fig. 3) supports this idea.

In conclusion, the results of our studies reveal an unanticipated genotoxic effect of sertraline that may partially explain the increased rate of birth defects in children of pregnant women taking the drug. They also suggest that potential negative effects of sertraline may be mitigated by endogenous antioxidant enzymes and/or supplementation with antioxidant compounds – a regime that does not utilize drugs with additional potential side effects, and thus is a very low-risk, likely high patient-compliance approach for optimizing fetal health.


Drosophila stocks and mutants

All experiments were carried out using stocks of Drosophila melanogaster that were maintained at 25 °C on a 12hr light:12hr dark cycle. Oregon-R (Bloomington stock number 25211) and SerT knockout (Bloomington stock number 36004) stocks were obtained from the Bloomington Drosophila Stock Center. The SertT knockout (y1 w*; Mi[MIC]SerTMI02578) has a Minos-Mediated Integration Cassette (MiMIC) transposon70, containing stop codons in all three reading frames, inserted into intron 3 of the SerT gene. RT-PCR was used to verify the lack of functional SerT transcript. Flies isogenic to the SerT knockout strain, but with an intact SerT gene, were created through excision of the SerTMI02578 transposon by crossing to flies carrying the Minos transposase (w1118; nocSco/SM6a, P{hs/MiT-2.4}, Bloomington stock 24613). Precise excision of the transposon was verified by Sanger sequencing.

Capillary feeder (CAFE) assays

Eight, 3-to-4-day-old, adult female flies were placed into a CAFE apparatus49 with capillary tubes containing either 5% sucrose or 5% sucrose + 250 μg/mL sertraline for 8 hours at 25 °C. Control CAFEs did not contain any flies. After 4 hours, capillary tubes were filled with additional solution. The volume of liquid lost due to evaporation in the control capillary tubes was calculated and subtracted from the volume of liquid lost in capillary tubes present in the fly-containing CAFEs. This allowed for calculation of the amount of liquid consumed by the flies, while also accounting for evaporation.

Measurement of adult female fecundity and egg-hatching frequency

Cohorts of eight female flies were fed sucrose or sertraline using the CAFE assay49, then anesthetized using carbon dioxide gas and placed into cages capped with grape juice agar plates with equal numbers of male flies. Embryos were collected for 18 hours and the numbers of hatched and unhatched embryos were counted 48 hours after removal of the females. Hatching frequencies were calculated based on at least three trials. The first instar larvae that hatched from these eggs were then transferred to cornmeal medium so that they could be followed to adulthood to observe possible abnormalities. Statistical analysis for fecundity and hatching frequency was performed using two-tailed, unpaired t-tests.

Preparation of food

Drosophila food was prepared by mixing Jazz-Mix (Fisher Scientific) with the manufacturer recommended amount of water and boiling for 5 minutes. Sertraline solution was prepared at concentrations of 50–500 µg/mL in 1% dimethyl sulfoxide (DMSO) solution and incubated at 55 °C until fully dissolved. For the larval feeding experiments, 500 µL of the solution was added to 4.5 mL of cooled (~55 °C) liquid food for final concentrations of 5–50 µg/mL sertraline. Control food was prepared by adding 500 μL of 1% DMSO solution without sertraline to 4.5 mL of cooled liquid food. For the antioxidant experiments, ascorbic acid was dissolved in water and added directly to the cooled liquid food.

Developmental stage tracking

Flies were placed into collection cages with grape juice agar plates and yeast paste to collect embryos. The agar plates were removed after two hours and incubated at 25 °C overnight. 20–25 first instar larvae were individually transferred into vials containing the appropriate food solution within four hours of hatching. Transfers were done with a metal probe, being careful not to injure the larvae. These vials were kept at 25 °C, and the number of wandering third instar larvae (based on size and wandering behavior), pupae, and eclosed adults was tallied every 12–24 hours, depending on the experiment. Statistical analysis was performed using a one-way ANOVA with Bonferroni correction.

Quantifying DNA damage and apoptosis

Wing imaginal discs were dissected from wandering third instar larvae71,72 and incubated in 100 µL of 0.7% NaCl solution containing 20% fetal bovine serum with either 0.02% dimethyl sulfoxide (DMSO) or 10 µg/mL sertraline in 0.02% DMSO for 5 hours at 25 °C. For measurement of ascorbic acid’s effects on DNA damage and apoptosis, 10 µg/mL sertraline solution was compared to 10 µg/mL sertraline solution containing increasing concentrations of ascorbic acid (0.2, 4, 8, and 16 mM) in separate trials. Treated discs were fixed with 1.48% formaldehyde for 30 minutes and incubated overnight with a 1:500 dilution of primary antibody anti-γ-H2Av (Rockland Inc.) or 1:100 dilution of Dcp-1 (Cell Signaling Technology). After 2 hours of incubation with secondary antibody solution (1:1000 goat anti-Rabbit IgG Rhodamine Red conjugated (Invitrogen) and 50 μg/mL DAPI in blocking solution), discs were mounted on microscope slides in 30 µL VECTASHIELD™ droplets and imaged with a Zeiss Z-stacking microscope using a 40X objective. 10–15 individual image slices from a Z-stack of the entire width of each wing disc were deconvolved using ZenPro image processing and stacked into one extended depth of field for each channel. A DsRed filter was used to visualize γ-H2Av or Dcp-1 foci, while a DAPI filter was used to visualize individual cell nuclei. ImageJ was used to quantify the number of γ-H2Av or Dcp-1 foci. Background in DsRed images was reduced until only foci were visible using intermodes auto-thresholding73, one of the most stringent means of histogram thresholding available, to ensure that background signal did not falsely inflate foci counts. All particles larger than 4 square microns were counted as foci. DAPI images were used to determine the area of each wing disc tested. γ-H2Av and Dcp-1 foci were normalized to wing disc area.

Measurement of reactive oxygen species formation

The formation of reactive oxygen species was measured through dihydroethidium (DHE) staining. Sertraline solution was prepared at a concentration of 500 µg/mL in 10% DMSO and compared to 10% DMSO in picopure water as a negative control. Imaginal wing discs were dissected from third instar larvae and incubated in culture media containing each solution for 5 hours at 25 °C as described. Discs were incubated in 30 µM DHE solution (Thermo Fisher Scientific) for 6 mins protected from light, fixed in 7% formaldehyde for 5 minutes, washed with PBS, and immediately imaged using the RFP filter on a Zeiss Z-stacking microscope.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.


  1. 1.

    Sghendo, L. & Mifsud, J. Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model. J. Pharm. Pharmacology 64, 317–325, (2012).

    CAS  Article  Google Scholar 

  2. 2.

    Levin, M., Buznikov, G. A. & Lauder, J. M. Of minds and embryos: left-right asymmetry and the serotonergic controls of pre-neural morphogenesis. Developmental Neurosci. 28, 171–185, (2006).

    CAS  Article  Google Scholar 

  3. 3.

    Vitalis, T. & Parnavelas, J. G. The role of serotonin in early cortical development. Dev. Neurosci. 25, 245–256, (2003).

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Gaspar, P., Cases, O. & Maroteaux, L. The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 4, 1002–1012 (2003).

    CAS  Article  Google Scholar 

  5. 5.

    Schroeter, S. & Blakely, R. D. Drug targets in the embryo. Studies on the cocaine- and antidepressant-sensitive serotonin transporter. Ann. NY. Acad. Sci. 801, 239–255 (1996).

    ADS  CAS  Article  Google Scholar 

  6. 6.

    Shuey, D. L., Yavarone, M., Sadler, T. W. & Lauder, J. M. Serotonin and morphogenesis in the cultured mouse embryo. Adv. Exp. Med. Biol. 265, 205–215 (1990).

    CAS  Article  Google Scholar 

  7. 7.

    Lobikin, M. et al. Serotonergic regulation of melanocyte conversion: A bioelectrically regulated network for stochastic all-or-none hyperpigmentation. Sci. Signal. 8, ra99, (2015).

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Lobikin, M., Chernet, B., Lobo, D. & Levin, M. Resting potential, oncogene-induced tumorigenesis, and metastasis: the bioelectric basis of cancer in vivo. Phys. Biol. 9, 065002, (2012).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Blackiston, D., Adams, D. S., Lemire, J. M., Lobikin, M. & Levin, M. Transmembrane potential of GlyCl-expressing instructor cells induces a neoplastic-like conversion of melanocytes via a serotonergic pathway. Dis. Model. mechanisms 4, 67–85, (2011).

    CAS  Article  Google Scholar 

  10. 10.

    Trevino, L. A., Ruble, M. W., Trevino, K., Weinstein, L. M. & Gresky, D. P. Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder. Psychiatr. Serv. 68, 199–202, (2017).

    Article  PubMed  Google Scholar 

  11. 11.

    Davies, T. S. & Kluwe, W. M. Preclinical toxicological evaluation of sertraline hydrochloride. Drug. Chem. Toxicol. 21, 521–537, (1998).

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Bozkurt, G. et al. Clastogenicity of selective serotonin-reuptake inhibitors. Mutat. Res. 558, 137–144, (2004).

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Scheffel, U., Kim, S., Cline, E. J. & Kuhar, M. J. Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: in vivo studies with [125I]RTI-55. Synap. 16, 263–268 (1994).

    CAS  Article  Google Scholar 

  14. 14.

    Yavarone, M. S., Shuey, D. L., Tamir, H., Sadler, T. W. & Lauder, J. M. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 47, 573–584, (1993).

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Shuey, D. L., Sadler, T. W. & Lauder, J. M. Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 46, 367–378 (1992).

    CAS  Article  Google Scholar 

  16. 16.

    Kalyoncu, N. I., Ozyavuz, R. & Karaoglu, S. Sertraline inhibits the contractile responses to noradrenaline, KCl and electrical field stimulation of rat isolated vas deferens. J. Auton. Pharmacol. 19, 365–369 (1999).

    CAS  Article  Google Scholar 

  17. 17.

    Ohno, Y., Hibino, H., Lossin, C., Inanobe, A. & Kurachi, Y. Inhibition of astroglial Kir4.1 channels by selective serotonin reuptake inhibitors. Brain Res. 1178, 44–51, (2007).

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Reddy, K. K. et al. The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Pigment. Cell melanoma Res. 21, 451–456, (2008).

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Wang, G. K., Mitchell, J. & Wang, S. Y. Block of persistent late Na+ currents by antidepressant sertraline and paroxetine. J. Membr. Biol. 222, 79–90, (2008).

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Amit, B. H. et al. Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro. Eur. neuropsychopharmacology: J. Eur. Coll. Neuropsychopharmacology 19, 726–734, (2009).

    CAS  Article  Google Scholar 

  21. 21.

    Huang, C. J. et al. Effect of the antidepressant sertraline on Ca2+ fluxes in Madin-Darby canine renal tubular cells. J. Recept. Signal. Transduct. Res. 29, 342–348, (2009).

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Wichman, C. et al. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J. Clin. Psychopharmacol. 28, 714–716 (2008).

    Article  Google Scholar 

  23. 23.

    Reefhuis, J. et al. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. BMJ 351, h3190, (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Shen, Z. Q. et al. Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies. Br. J. Clin. Pharmacol. 83, 909–922, (2017).

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Pedersen, L. H., Henriksen, T. B., Vestergaard, M., Olsen, J. & Bech, B. H. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339, b3569, (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Bérard, A., Zhao, J.-P. & Sheehy, O. Sertraline use during pregnancy and the risk of major malformations. Am. J. Obstet. Gynecol. 212, 795.e791–795.e712, (2015).

    CAS  Article  Google Scholar 

  27. 27.

    Louik, C., Lin, A. E., Werler, M. M., Hernández-Díaz, S. & Mitchell, A. A. First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. N. Engl. J. Med. 356, 2675–2683, (2007).

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Harrington, R. A., Lee, L.-C., Crum, R. M., Zimmerman, A. W. & Hertz-Picciotto, I. Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay. Pediatrics, peds. 2013-3406, (2014).

    Article  Google Scholar 

  29. 29.

    Yazdy, M. M., Mitchell, A. A., Louik, C. & Werler, M. M. Use of Selective Serotonin-Reuptake Inhibitors during Pregnancy and the Risk of Clubfoot. Epidemiol. 25, 859–865, (2014).

    Article  Google Scholar 

  30. 30.

    Chambers, C. D. et al. Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. N. Engl. J. Med. 354, 579–587, (2006).

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Oberlander, T. F., Warburton, W., Misri, S., Aghajanian, J. & Hertzman, C. Neonatal Outcomes After Prenatal Exposure to Selective Serotonin Reuptake Inhibitor Antidepressants and Maternal Depression Using Population-Based Linked Health Data. Arch. Gen. Psychiatry 63, 898–906, (2006).

    Article  PubMed  Google Scholar 

  32. 32.

    Suri, R. et al. Effects of Antenatal Depression and Antidepressant Treatment on Gestational Age at Birth and Risk of Preterm Birth. Am. J. Psychiatry 164, 1206–1213, (2007).

    Article  PubMed  Google Scholar 

  33. 33.

    Gentile, S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug. safety: an. Int. J. Med. Toxicol. drug. experience 28, 137–152 (2005).

    CAS  Article  Google Scholar 

  34. 34.

    Andalib, S. et al. Maternal SSRI exposure increases the risk of autistic offspring: A meta-analysis and systematic review. Eur. Psychiatry 45, 161–166, (2017).

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Levinson-Castiel, R., Merlob, P., Linder, N., Sirota, L. & Klinger, G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch. pediatrics Adolesc. Med. 160, 173–176, (2006).

    Article  Google Scholar 

  36. 36.

    McDowell, G., Rajadurai, S. & Levin, M. From cytoskeletal dynamics to organ asymmetry: a nonlinear, regulative pathway underlies left-right patterning. Philos. Trans. R. Soc. Lond. B Biol. Sci. 371, 20150409 (2016).

    Article  Google Scholar 

  37. 37.

    Hernandez-Diaz, S. & Levin, M. Alteration of bioelectrically-controlled processes in the embryo: a teratogenic mechanism for anticonvulsants. Reprod. Toxicol. 47, 111–114, (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Fukumoto, T., Kema, I. P. & Levin, M. Serotonin signaling is a very early step in patterning of the left-right axis in chick and frog embryos. Curr. Biol. 15, 794–803 (2005).

    CAS  Article  Google Scholar 

  39. 39.

    Fukumoto, T., Blakely, R. & Levin, M. Serotonin transporter function is an early step in left-right patterning in chick and frog embryos. Dev. Neurosci. 27, 349–363 (2005).

    CAS  Article  Google Scholar 

  40. 40.

    Conners, D. E., Rogers, E. D., Armbrust, K. L., Kwon, J. W. & Black, M. C. Growth and development of tadpoles (Xenopus laevis) exposed to selective serotonin reuptake inhibitors, fluoxetine and sertraline, throughout metamorphosis. Environ. Toxicol. Chem. / SETAC 28, 2671–2676 (2009).

    CAS  Article  Google Scholar 

  41. 41.

    Sen, A. & Cox, R. T. Fly Models of Human Diseases: Drosophila as a Model for Understanding Human Mitochondrial Mutations and Disease. Curr. Top. Dev. Biol. 121, 1–27, (2017).

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Coutelis, J. B., Petzoldt, A. G., Speder, P., Suzanne, M. & Noselli, S. Left-right asymmetry in Drosophila. Semin Cell Dev Biol (2008).

  43. 43.

    Cheng, L., Baonza, A. & Grifoni, D. Drosophila Models of Human Disease. Biomed. Res. Int. 2018, 7214974, (2018).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Pandey, U. B. & Nichols, C. D. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol. Rev. 63, 411–436, (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Colas, J. F., Launay, J. M. & Maroteaux, L. Maternal and zygotic control of serotonin biosynthesis are both necessary for Drosophila germband extension. Mech. Dev. 87, 67–76 (1999).

    CAS  Article  Google Scholar 

  46. 46.

    Colas, J. F., Launay, J. M., Vonesch, J. L., Hickel, P. & Maroteaux, L. Serotonin synchronises convergent extension of ectoderm with morphogenetic gastrulation movements in Drosophila. Mech. Dev. 87, 77–91 (1999).

    CAS  Article  Google Scholar 

  47. 47.

    Thurmond, J. et al. FlyBase 2.0: the next generation. Nucleic Acids Res. 47, D759–D765, (2019).

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Gurbuzel, M., Oral, E., Kizilet, H., Halici, Z. & Gulec, M. Genotoxic evaluation of selective serotonin-reuptake inhibitors by use of the somatic mutation and recombination test in Drosophila melanogaster. Mutat. Res. 748, 17–20, (2012).

    CAS  Article  PubMed  Google Scholar 

  49. 49.

    Ja, W. W. et al. Prandiology of Drosophila and the CAFE assay. Proc. Natl Acad. Sci. USA 104, 8253–8256, (2007).

    ADS  CAS  Article  PubMed  Google Scholar 

  50. 50.

    Poodry, C. A. & Woods, D. F. Control of the developmental timer forDrosophila pupariation. Roux Arch. Dev. Biol. 199, 219–227, (1990).

    Article  PubMed  Google Scholar 

  51. 51.

    Stieper, B. C., Kupershtok, M., Driscoll, M. V. & Shingleton, A. W. Imaginal discs regulate developmental timing in Drosophila melanogaster. Dev. Biol. 321, 18–26, (2008).

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Wells, B. S. & Johnston, L. A. Maintenance of imaginal disc plasticity and regenerative potential in Drosophila by p53. Developmental Biol. 361, 263–276, (2012).

    CAS  Article  Google Scholar 

  53. 53.

    Khodaverdian, V. Y. & McVey, M. in Fast Detection of DNA Damage Methods in Molecular Biology 203-211 (Humana Press, New York, NY, 2017).

  54. 54.

    Madigan, J. P., Chotkowski, H. L. & Glaser, R. L. DNA double-strand break-induced phosphorylation of Drosophila histone variant H2Av helps prevent radiation-induced apoptosis. Nucleic Acids Res. 30, 3698–3705 (2002).

    CAS  Article  Google Scholar 

  55. 55.

    Rogakou, E. P., Boon, C., Redon, C. & Bonner, W. M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol. 146, 905–916, (1999).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Sarkissian, T., Timmons, A., Arya, R., Abdelwahid, E. & White, K. Detecting apoptosis in Drosophila tissues and cells. Methods 68, 89–96, (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Song, Z., McCall, K. & Steller, H. DCP-1, a Drosophila cell death protease essential for development. Sci. 275, 536–540 (1997).

    CAS  Article  Google Scholar 

  58. 58.

    Verghese, S. & Su, T. T. Drosophila Wnt and STAT Define Apoptosis-Resistant Epithelial Cells for Tissue Regeneration after Irradiation. PLoS Biol 14, (2016).

    Article  Google Scholar 

  59. 59.

    Chen, J., Korostyshevsky, D., Lee, S. & Perlstein, E. O. Accumulation of an Antidepressant in Vesiculogenic Membranes of Yeast Cells Triggers Autophagy. PLoS ONE 7, (2012).

    ADS  CAS  Article  Google Scholar 

  60. 60.

    Dorraji, P. S. & Jalali, F. Investigation of the interaction of sertraline with calf thymus DNA by spectroscopic methods. J. Braz. Chem. Soc. 24, 939–945, (2013).

    CAS  Article  Google Scholar 

  61. 61.

    Rehmani, N., Farhan, M. & Hadi, S. M. 4. DNA Binding and its Degradation by the Neurotransmitter Serotonin and its Structural Analogues Melatonin and Tryptophan: Putative Neurotoxic Mechanism. Journal of Molecular and Genetic Medicine 10 (2016).

  62. 62.

    Hadi, N., Malik, A., Azam, S., Khan, N. U. & Iqbal, J. Serotonin–Cu(II)-mediated DNA cleavage: mechanism of copper binding by serotonin. Toxicol. Vitro 16, 669–674, (2002).

    CAS  Article  Google Scholar 

  63. 63.

    Owusu-Ansah, E. & Banerjee, U. Reactive oxygen species prime Drosophila haematopoietic progenitors for differentiation. Nat. 461, 537–541, (2009).

    ADS  CAS  Article  Google Scholar 

  64. 64.

    DeVane, C. L., Liston, H. L. & Markowitz, J. S. Clinical pharmacokinetics of sertraline. Clin. Pharmacokinet. 41, 1247–1266, (2002).

    CAS  Article  PubMed  Google Scholar 

  65. 65.

    Durant, F. et al. Long-Term, Stochastic Editing of Regenerative Anatomy via Targeting Endogenous Bioelectric Gradients. Biophys. J. 112, 2231–2243, (2017).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Brock, A., Chang, H. & Huang, S. Non-genetic heterogeneity–a mutation-independent driving force for the somatic evolution of tumours. Nat. Rev. Genet. 10, 336–342, (2009).

    CAS  Article  PubMed  Google Scholar 

  67. 67.

    Cloonan, S. M., Drozgowska, A., Fayne, D. & Williams, D. C. The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leukemia Lymphoma 51, 523–539, (2010).

    CAS  Article  PubMed  Google Scholar 

  68. 68.

    Gil-Ad, I. et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int. J. Oncol. 33, 277–286, (2008).

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Lin, C.-J., Robert, F., Sukarieh, R., Michnick, S. & Pelletier, J. The Antidepressant Sertraline Inhibits Translation Initiation by Curtailing Mammalian Target of Rapamycin Signaling. Cancer Res. 70, 3199–3208, (2010).

    CAS  Article  PubMed  Google Scholar 

  70. 70.

    Nagarkar-Jaiswal, S. et al. A library of MiMICs allows tagging of genes and reversible, spatial and temporal knockdown of proteins in Drosophila. elife 4, e05338, (2015).

    CAS  Article  PubMed Central  Google Scholar 

  71. 71.

    Phalle Bde, S. Immunostaining of whole-mount imaginal discs. Methods Mol. Biol. 247, 373–387, (2004).

    Article  PubMed  Google Scholar 

  72. 72.

    Spratford, C. M. & Kumar, J. P. Dissection and immunostaining of imaginal discs from Drosophila melanogaster. J Vis Exp, 51792, (2014).

  73. 73.

    Prewitt, J. M. S. & Mendelsohn, M. L. The Analysis of Cell Images*. Ann. N. Y. Acad. Sci. 128, 1035–1053, (1966).

    ADS  CAS  Article  PubMed  Google Scholar 

Download references


We thank the Bloomington Drosophila Stock Center for fly stocks and Varandt Khodaverdian for advice regarding the imaginal disc staining experiments. M.L. gratefully acknowledges support from the Allen Discovery Center program through The Paul G. Allen Frontiers Group (12171) and the Barton Family Foundation. M.M. acknowledges support from NIH grant P01GM105473.

Author information




Conceptualization, M.M. and M.L; Methodology, C.D., A.J. and S.S; Formal Analysis, C.D., A.J. and M.M.; Investigation, C.D., A.J. and S.S; Writing –Original Draft, A.J. and M.M.; Writing –Review & Editing, C.D., A.J., M.L. and M.M.; Funding Acquisition, M.L. and M.M.; Supervision, M.L. and M.M.

Corresponding author

Correspondence to Mitch McVey.

Ethics declarations

Competing interests

The authors declare no financial competing interests. M.L. occasionally serves as an expert witness in litigation involving SSRI drugs.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jajoo, A., Donlon, C., Shnayder, S. et al. Sertraline induces DNA damage and cellular toxicity in Drosophila that can be ameliorated by antioxidants. Sci Rep 10, 4512 (2020).

Download citation


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing